Single-payer pharmacare is a cure worse than what ails the system
A federal intrusion that disrupts coverage for three-quarters of the population, requires tax hikes and spending cuts, and leads to less drug access hardly seems like a political winner. But neither is silence on the other side of the debate.
A single-payer pharmacare scheme would disrupt coverage for the 77 per cent of the population generally satisfied with the status quo, argues Sean Speer. Photograph courtesy of Victor Casale